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Abstract: In immature rodent brain, the glutamate receptor 
agonist N-methyl-D-aspartate (NMDA) is a potent neuro- 
toxin. In postnatal day (PND)-7 rats, intrastriatal injection 
of 25 nmol of NMDA results in extensive ipsilateral forebrain 
injury. In this study, we examined alterations in high-affinity 
[3H]glutamate uptake (HAGU) in NMDA-lesioned striatum. 
HAGU was assayed in synaptosomes, prepared from lesioned 
striaturn, the corresponding contralateral striaturn, or unle- 
sioned controls. Twenty-four hours after NMDA injection 
(25 nmol), HAGU declined 44 t 8% in lesioned tissue, com- 
pared with the contralateral striatum (mean t SEM, n = 6 
assays, p < 0.006, paired t test). Doses of 5-25 nmol of NMDA 
resulted in increasing suppression of HAGU (5 nmol, n = 3; 
12.5 nmol, n = 3; and 25 nmol, n = 5 assays; p < 0.01, 
regression analysis). The temporal evolution of HAGU 
suppression was biphasic. There was an early transient 
suppression of HAGU (-28 t 4% at 1 h; p < 0.03, analysis 
of variance, comparing changes at 0.5, 1, 2, and 3 h after 
lesioning); I or 5 days postinjury there was sustained loss of 
HAGU (at 5 days, -56 5 1 1 %, n = 3, p < 0.03, paired t test, 
lesioned versus contralateral striata). Treatment with the 
noncompetitive NMDA antagonist MK-80 1 (1 mg/kg i.p.) 
attenuated both the early and subsequent irreversible 
suppression of HAGU (1 h postlesion -28 f 4%, n = 6 assays 
versus -12.6 t 5% with MK-801, n = 4, p = 0.005; 24 h 
postlesion, -44 t 8%, n = 5, versus $2.4 t 6%, n = 3 with 
MK-80 I,  p = 0.0 I ,  Wilcoxon ranked sum tests). In immature 
brain excitotoxic lesions produce an acute reversible 
suppression of HAGU, and a delayed long-lasting reduction 
in HAGU secondary to brain injury. These data suggest that 
accumulation of endogenous glutamate, as a consequence of 
the acute disruption of HAGU, could contribute to the 
pathogenesis of excitotoxic neuronal injury. Key Words: 
Perinatal-N-Methyl-D-aspartate-Glutamate-Striatum- 
Uptake-Injury. Hu B. et al. Excitotoxic brain injury sup- 
presses striatal high-affinity glutamate uptake in perinatal rats. 
J. Neurochem. 56,933-937 (1991). 
The selective glutamate receptor agonist N-methyl- 
D-aspartate (NMDA) is a potent neurotoxin in the de- 
veloping brain (McDonald et al., 1988). Unilateral in- 
trastriatal injection of NMDA in postnatal day (PND)- 
7 rats produces an ipsilateral forebrain lesion; doses of 
5-25 nmol of NMDA result in progressive reductions 
in tissue mass, regional cross-sectional areas, and cho- 
line acetyltransferase (ChAT) activity (McDonald et 
al., 1989~). Systemic administration of the noncom- 
petitive NMDA antagonist MK-80 1 prevents NMDA- 
induced tissue damage (Foster et al., 1987, 1988; 
McDonald et al., 1989b). 
Excitatory amino acid (EAA) neurotransmitters are 
rapidly removed from the synaptic cleft by reuptake 
into glutamatergic nerve terminals and glia (Fonnum, 
1984). Suppression of reuptake could thus result in 
increased or prolonged synaptic accumulation of re- 
leased transmitter. The role of endogenous EAA in the 
pathogenesis of NMDA-induced injury is uncertain. 
Previously, in a model of perinatal hypoxic-ischemic 
brain injury, we found that there was a marked, re- 
versible suppression of high-affinity [3H]glutamate up- 
take (HAGU) in synaptosomes prepared from acutely 
lesioned striatum (Silverstein et al., 1986). Reductions 
in HAGU activity appeared to precede the onset of 
irreversible neuronal damage and our data suggested 
that this functional disruption could represent a 
pathophysiologic mechanism whereby EAA could ac- 
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cumulate at the synaptic cleft and contribute to the 
evolution of ischemic brain injury. 
Synaptosomal HAGU assays enable measurement 
of sodium-dependent uptake of [3H]glutamate in vitro 
and provide a method for assessment of the functional 
integrity of striatal presynaptic glutamatergic nerve 
terminals (Bennett et al., 1973). In PND-7 rats, striatal 
HAGU activity is considerably lower than in adult 
brain, presumably reflecting immaturity of striatal glu- 
tamatergic innervation (Campochiaro and Coyle, 
1978). In this study, we examined the impact of in- 
trastriatal NMDA injections on striatal HAGU to de- 
termine if excitotoxic lesions disrupted HAGU in im- 
mature rat brain. We assessed the dose-response char- 
acteristics and time course of NMDA-induced 
suppression of striatal HAGU, and the extent to which 
treatment with the noncompetitive NMDA antagonist 
MK-80 1 (Wong et al., 1986) preserved HAGU. Based 
on the hypothesis that increased concentrations of free 
fatty acids could suppress HAGU activity acutely 
(Rhoads et al., 1982; Chan et al., 1983) and on  the 
observation that incubation of synaptosomes from 
hypoxic-ischemic striatum with albumin restored 
HAGU activity (Silverstein et al., 1986), we also de- 
termined the effects of albumin on HAGU in NMDA- 
lesioned striatum. 
MATERIALS AND METHODS 
Animal preparation 
PND-7 Sprague-Dawley rats were anesthetized with ether 
for 3 min. Stereotaxically guided intrastriatal NMDA injec- 
tions were performed as previously described by McDonald 
et al. (1989~). After a midline scalp incision was made to 
expose the calvarium, the injection site was identified using 
bregma as a landmark (coordinates: AP 2.0 mm, L 2.5 mm, 
depth 4 mm.). A Kopf small animal stereotaxic apparatus 
was used to guide injections, which were done with a 26- 
gauge Hamilton syringe. NMDA (5-25 nmol) was dissolved 
in 0.01 M Tris, pH 7.4, and injected over 2 min (volume, 
0.5 pl). The scalp was sutured, and rats were allowed to re- 
cover under a warming lamp. When MK-801 was adminis- 
tered, 1 mg/kg was injected intrapentoneally (volume, 0.1 
ml) 15 min after the NMDA injection, and littermate NMDA- 
lesioned controls were injected with equal volumes of saline. 
Animals were killed by decapitation, and striata were quickly 
dissected on ice. 
Eighteen experiments were done (mean number of animals 
per experiment = 11). The surgical protocol was approved 
by the University of Michigan Committee on Care and Use 
of Animals. 
HAGU assay 
Sodiumdependent HAGU was measured according to the 
methods of Bennett et al. (1973). Each experiment included 
striatal samples from the side of lesioning, the contralateral 
hemisphere, and unlesioned or saline-injected littermate 
controls. For each synaptosome preparation, tissue from two 
corresponding striata were pooled; final values were averaged 
from triplicate synaptosome preparations assayed concur- 
rently. 
Tissue and reagents were kept on ice. Tissue was homog- 
enized 1:20 in isotonic sucrose (0.32 M ) ,  the P2 fraction was 
isolated by repeated centrifugation and resuspended in 200 
p1 of sucrose. Four 25-pl aliquots of the synaptosome pellet 
(duplicate samples and blanks) were incubated for 10 min at 
37°C in 950 pl of Krebs-Ringer phosphate buffer, pH 7.4, 
with 14 Mglucose; in the buffer for blanks, choline chloride 
substituted for NaCI. In experiments to test albumin’s effects 
on HAGU, 1 mg/ml of bovine serum albumin (BSA, alcohol- 
precipitated, 95-99% pure, Sigma) was added to the incu- 
bation buffer. Then, 20 pl of [3H]glutamate (1 mCi/ml, 
Amersham, Arlington Heights, IL, U.S.A.) was added (20 pl 
[3H]glutamate in 1 ml of 5 p M  glutamate); after a 4-min 
incubation, HAGU was stopped by addition of excess cold 
sodium-deficient buffer, followed by centrifugation at 20,000 
g for 15 min. The pellet was dissolved in tissue solubilizer 
and accumulated radioactivity was counted. Counts in blanks 
were subtracted from total counts. The protein content in 
an aliquot of each synaptosome preparation was assayed 
(Bradford, 1976), and specific uptake per microgram of pro- 
tein was calculated. In these experiments (n = IS), HAGU 
activity in controls (mean 4 SEM) was 8.8 k 1 pmol/min/ 
mg of protein. 
Experimental protocols 
After preliminary data demonstrated a marked NMDA- 
induced reduction in striatal HAGU, four groups of experi- 
ments were done to characterize this response. 
To determine the relationship between the amount of 
NMDA injected and the extent of HAGU suppression, striatal 
HAGU was compared in synaptosomes derived from animals 
that received right intrastriatal injections of 5, 12.5, or 25 
nmol NMDA and were killed 24 h later (n = 3, 3, and 5 
assays, respectively). Higher NMDA doses were not tested 
because doses above 25 nmol result in increased mortality 
and bihemispheric tissue damage: 5 nmol is the lowest dose 
that reliably elicits histologic damage. 
To assess the temporal evolution of NMDA-induced 
HAGU suppression, side-side differences in striatal HAGU 
were compared in tissue from animals killed at 0.5, 1, 2, and 
3 h after NMDA lesioning (25 nmol, n = 1,6, 3, and 3 assays, 
respectively), and in animals killed 24 h or 5 days later (n 
= 5 and 3 assays, respectively). 
In one experiment, albumin-induced stimulation of 
HAGU was assessed. Saline- and NMDA-injected animals 
were killed 1 h postlesioning (n = 4 animals per group), syn- 
aptosomes were prepared from the injected and contralateral 
striata of each group, and HAGU was compared in aliquots 
from each synaptosome preparation incubated with or with- 
out added BSA ( 1  mg/ml). 
The neuroprotective actions of MK-801 were evaluated at 
two time intervals, 1 and 24 h postlesioning. In seven exper- 
iments, animals received intrastriatal injections of 25 nmol 
NMDA, half received 1 mg/kg MK-801 15 min later, and 
the others received an equal volume of saline. Animals were 
killed 1 (n = 4 assays) or 24 h (n = 3) later. For the data 
analysis, values from additional experiments in which animals 
had received the same dose of NMDA and were sacrificed at 
the same time interval were also included. 
Data analysis 
Because there was interassay variation in absolute values 
for HAGU, to incorporate results from multiple experiments, 
HAGU values in lesioned animals were expressed as per- 
J.  Neurochem., Vol. 56, No 3. 1991 
NMDA INHIBITS GLUTAMATE UPTAKE 935 
centage of HAGU in untreated littermate controls assayed 
in the same experiment. For these data n indicates number 
of independent experiments; values are means -+ SEM of 
triplicate assays, calculated as dpm/min/pg protein and ex- 
pressed as a percentage of HAGU in controls. 
In samples from lesioned animals, percent change was cal- 
culated as: [(percentage of HAGU activity in contralateral 
striaturn) - (percentage of HAGU activity in injected stria- 
tum)]/(percentage of HAGU activity in contralateral stria- 
tum); percent change values for the dose-response analysis 
were compared with regression analysis; values for the time- 
course analysis were compared with analysis of variance 
(ANOVA), and percent change values in untreated and MK- 
80 1 -treated animals were compared with Wilcoxon rank-sum 
tests. 
RESULTS 
Striatal HAGU was compared in synaptosomes from 
PND-7 animals that received right intrastriatal injec- 
tions of 5, 12.5, or 25 nmol of NMDA and were killed 
24 h later (Fig. 1); side-side differences at each dose 
were compared by regression analysis (p < 0.01). In 
tissue from the contralateral striatum HAGU did not 
change, whereas in tissue derived from the injected 
striatum there was a progressive, dose-related reduction 
in HAGU; at the highest dose tested HAGU declined 
44 f 8% (mean f SEM). 
The time-course analysis (Fig. 2) revealed a biphasic 
suppression of HAGU. Comparison of side-side dif- 
ferences in animals killed at 0.5, 1, 2, and 3 h after 
NMDA lesioning demonstrated a transient, reversible 
suppression of HAGU; HAGU was reduced at the ear- 
liest time intervals but activity was restored at 2-3 h 
(ANOVA, p < 0.03). Subsequently, in animals killed 
24 h or 5 days later, a marked reduction in HAGU in 
lesioned tissue persisted (at 24 h: -44 f 8%, p < 0.006 
paired t test comparing contralateral and lesioned 
striata, n = 6 assays; at 120 h, n = 3, -56 -t 1 1 % ,  p 
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FIG. 1. Striatal HAGU was compared in synaptosomes from PND- 
7 animals that received right intrastriatal injections of 5, 12.5, or 
25 nmol of NMDA and were killed 24 h later (n = 3, 3, and 5 
assays, respectively). In tissue from the hemisphere contralateral 
to the lesion, HAGU-L values, expressed as percent k SEM of 
activity in untreated controls, did not change, whereas in tissue 
derived from the injected striatum (HAGU-R) there was a progres- 
sive, doserelated reduction in HAGU. Side-side differences in each 
group were compared by regression analysis; *p < 0.01. 
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FIG. 2. Striatal HAGU was compared in synaptosomes from an- 
imals that received right intrastriatal injections of 25 nmol of NMDA 
and were killed 1 h to 5 days later. In tissue from the hemisphere 
contralateral to the lesion, HAGU-L values, expressed as percent 
k SEM of activity in samples from untreated controls assayed 
concurrently, did not change. In tissue from the injected striatum 
(HAGU-R) there was an initial transient reduction in HAGU, followed 
by a subsequent apparently irreversible loss of HAGU activity. Siie- 
side differences in animals killed at 0.5, 1, 2, and 3 h after NMDA 
lesioning were compared by ANOVA ('p < 0.03). HAGU in tissue 
derived from the contralateral and lesioned striata of animals killed 
24 h (n = 6 assays) or 120 h (n = 3) after lesioning were compared 
by paired, two-tailed t tests (*p  < 0.03; **p < 0.006). 
injections of saline and were killed 1 or 24 h or 5 days 
later, there were no side-side differences in HAGU 
(data not shown). In a single experiment, in vitro in- 
cubation of synaptosomes from untreated animals with 
NMDA (10-100 pM, for 2 min before addition of 
[3H]glutamate) suppressed HAGU by 20-26%. 
Addition of albumin to the incubation buffer stim- 
ulated HAGU in all tissue samples (p < 0.00 1 ,  paired 
t test); values increased by 39-56% in unlesioned tissue 
and by 89% in acutely lesioned striatum (Table 1). 
In NMDA-lesioned animals, administration of 1 mg/ 
kg of MK-80 1 attenuated NMDA-induced suppression 
of stnatal HAGU (Fig. 3). In animals killed 1 or 24 h 
TABLE 1. Efect of albumin on sodium-dependent 
/3Hlglutamate upake 
HAGU (pmol/min/ 
mg of protein) 
~ 
Source of tissue -BSA +BSA' Percent increase 
Saline-injected 
Contralateral 9.86 13.72 +39.1 
Ipsilateral 8.49 13.28 +56.5 
Contralateral 8.94 13.30 +48.8 
Ipsilateral 5.9 1 11.17 +88.9 
The extent of stimulation of HAGU elicited by addition of 1 mg/ 
ml of BSA to the incubation buffer was compared in synaptosome 
preparations derived from four saline-injected and four NMDA (25 
nmo1)-injected PND-7 rats. Animals were killed 1 h postinjection. 
Two striata were pooled per synaptosome preparation, and 
[3H]HAGU activity was assayed concurrently in -BSA and +BSA 
incubations buffers, as described in Materials and Methods. "p 
< 0.001, paired t test, comparing -BSA and fBSA. 
NMDA-injected 
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FIG. 3. Effects of MK-801 administration on the magnitude of 
NMDA-induced suppression of striatal HAGU were assessed at 
two time intervals, 1 h and 24 h postlesioning. In seven experiments. 
PND-7 rats received right intrastriatal injections of 25 nmd of NMDA 
and half received 1 mg/kg MK-801 by intraperitoneal injection 15 
min later and the others received an equal volume of saline. Animals 
were killed 1 h (n = 4 assays) or 24 h (n = 3) later. Values from 
additional experiments in which animals had received the same 
dose of NMDA and were killed at the same time intervals were 
also included in the data analysis. Side-side differences in HAGU 
(expressed as percent -t SEM of control values) were compared 
at each time interval in untreated and MK-801 -treated animals with 
Wilcoxon rank-sum tests (number of assays at 1 h: no treatment, 
n = 6, MK-801, n = 4; at 24 h: no treatment, n = 5, MK-801, n 
= 3). *p = 0.005; **p = 0.01. 
after lesioning HAGU was relatively preserved in the 
lesioned striatum of MK-80 1 -treated animals: at 1 h, 
-28 t 4% in untreated animals versus - 12.6 f 5% in 
MK-801-treated group, p = 0.005; at 24 h, -44 f 8% 
versus +2.4 k 6% after MK-80 1 treatment, p = 0.0 1, 
Wilcoxon rank-sum tests. 
DISCUSSION 
These data demonstrate that in PND-7 rats unilateral 
intrastriatal injections of NMDA resulted in dose-de- 
pendent suppression of HAGU. There was an early 
transient reduction in functional activity and subse- 
quent irreversible loss of HAGU; treatment with MK- 
80 1 blocked these effects. 
Although the methods used did not allow repeated 
measures in a single animal, the time-course data, based 
on values from animals killed at sequential time in- 
tervals after lesioning, indicated that suppression of 
HAGU was biphasic. Of interest, the acute, transient 
suppression of HAGU in NMDA-lesioned striatum 
paralleled the reversible loss of HAGU activity ob- 
served during the evolution of hypoxic-ischemic brain 
injury in PND-7 rats (Silverstein et al., 1986). Factors 
that could contribute to this early loss of functional 
activity include depletion of metabolic substrates re- 
quired to maintain membrane integrity, sustained 
membrane depolarization, or accumulation of toxic 
metabolites. For example, NMDA receptor activation 
stimulates arachidonic acid release (Dumuis et al., 
1988). Arachidonate inhibits HAGU in vitro (Rhoads 
et al., 1982; Chan et al., 1983; Barbour et al., 1989) 
and may act similarly in vivo; the observed stimulatory 
effects of albumin on HAGU may well be attributable 
to chelation of arachidonate and other free fatty acids 
(Rhoads et al., 1982). It is surprising that preincubation 
of synaptosomes in a glucose-containing, physiologic 
buffer did not abolish any NMDA-induced metabolic 
derangements or membrane potential changes that 
contributed to the acute suppression of HAGU ob- 
served. 
Irreversible loss of HAGU most likely reflects struc- 
tural damage to specific glutamate recognition or car- 
rier sites on presynaptic nerve terminals or on glia. 
Damage to cortico-striatal afferent neurons or to glu- 
tamatergic nerve terminals within striatum could con- 
tribute to loss of HAGU activity. Intrastriatal NMDA 
injections result in injury to adjacent, overlying cortex 
(McDonald et al., 1988) and the reductions in striatal 
HAGU could, in part, result from damage to cortico- 
striatal afferent neurons. However, based on previous 
studies of the patterns of neurotoxicity of the glutamate 
analogue kainate, relative sparing of presynaptic glu- 
tamatergic nerve terminals might have been expected 
in NMDA-lesioned animals (Coyle and Schwarcz, 
1976; Coyle et al., 1978; Vincent and McGeer, 1980). 
After intrastriatal injection of kainic acid (5 nmol) in 
adult brain, HAGU activity was unchanged whereas 
ChAT activity, a marker of intrinsic striatal cholinergic 
neurons, decreased by 70% (Vincent and McGeer, 
1980). Previously, we found a direct linear relationship 
between the dose of NMDA injected intrastriatally and 
the extent of tissue damage (over the range 5-25 nmol) 
in PND-7 rats (McDonald et al., 1989~). ChAT activity, 
declined to a similar extent in NMDA-lesioned stria- 
tum. In animals killed 5 days after intrastriatal injection 
of NMDA (25 nmol), the magnitude of reductions in 
striatal cross-sectional area, ChAT activity, and HAGU 
were similar and indicated no selective sparing of pre- 
synaptic nerve terminals. 
NMDA neurotoxicity is presumably mediated di- 
rectly by receptor activation (Rothman and Olney, 
1987). Both competitive and noncompetitive NMDA 
antagonists block NMDA-induced neuronal damage 
(Foster et al., 1988; McDonald et al., 1989~). The abil- 
ity of MK-80 1 treatment to limit NMDA-induced re- 
ductions in HAGU suggested that loss of uptake activ- 
ity was a consequence of NMDA receptor activation. 
Yet, in striatum, NMDA receptors are concentrated 
postsynaptically (Greenamyre and Young, 1989) 
whereas glutamate uptake sites are localized presyn- 
aptically (Vincent and McGeer, 1980). Thus, NMDA- 
induced damage to presynaptic glutamatergic terminals 
is likely to be mediated indirectly, and result from fac- 
tors such as energy depletion, accumulation of toxic 
metabolites, or damage to protective inhibitory neu- 
rons. 
Synaptosomal HAGU could also, in part, reflect glial 
rather than neuronal glutamate uptake activity. How- 
ever, 5 days after NMDA lesioning there is prominent 
gliosis (Silverstein, unpublished observation). If the glial 
contribution to HAGU were significant, increased ac- 
J Neurochem., Val. 56, No. 3, 1991 
NMDA INHI3ITS GLUTAMATE UPTAKE 937 
tivity, rather than the pronounced decrease observed, 
would be expected. 
Several lines of investigation indicate that NMDA- 
induced neuronal damage progresses for hours after 
initial exposure (Rothman et al., 1987; Foster et al., 
1988; McDonald et a]., 1990). In this experimental 
model, MK-801 administration up to 2 h after intra- 
striatal NMDA lesioning prevents >90% of tissue 
damage (McDonald et al., 1990). The role of endoge- 
nous EAA neurotransmitters in the pathogenesis of 
NMDA-induced damage in vivo is uncertain. Inhibi- 
tion of HAGU could contribute to accumulation of 
toxic concentrations of EAA at the synapse (Kohler 
and Schwarcz, 198 1). Our data suggest that in the im- 
mature brain presynaptic mechanisms such as 
suppression of HAGU may play an important role in 
the evolution of excitotoxic neuronal injury. 
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